Page 939 - Williams Hematology ( PDFDrive )

914 Part VI: The Erythrocyte <CN>: <ct> PB

315. Rossini A, Contessi GB, Leali C, et al: Efficacy of iron depletion and antiviral therapy 319. Stevens BR, Fleischer AB, Piering F, et al: Porphyria cutanea tarda in the setting of
in patients with porphyria cutanea tarda (PCT) and hepatitis C virus (HCV) chronic renal failure: Response to renal transplantation. Arch Dermatol 129:337, 1993.
infection [abstract]. Hepatology 40(Suppl 1):320A, 2004. 320. Fontanellas A, Mazurier F, Moreau-Gaudry F, et al: Correction of uroporphyrinogen
316. Shieh S, Cohen JL, Lim HW: Management of porphyria cutanea tarda in the setting of decarboxylase deficiency (hepatoerythropoietic porphyria) in Epstein-Barr virus-trans-
chronic renal failure: A case report and review. J Am Acad Dermatol 42(4):645, 2000. formed B-cell lines by retrovirus-mediated gene transfer: Fluorescence-based selection
317. Yaqoob M, Smyth J, Ahmad R, et al: Haemodialysis-related porphyria cutanea tarda of transduced cells. Blood 94(2):465, 1999.
and treatment by recombinant human erythropoietin. Nephron 60:428, 1992.
318. Carson RW, Dunnigan EJ, DuBose TDJ, et al: Removal of plasma porphyrins with
high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal dis-
ease. J Am Soc Nephrol 2:1445, 1992.

Kaushansky_chapter 58_p0889-0914.indd 914 9/18/15 5:58 PM